Last $391.75 MXN
Change Today +0.08 / 0.02%
Volume 152.0
PFE* On Other Exchanges
Symbol
Exchange
New York
Xetra
Mexico
SIX Swiss Ex
Stockholm
London
EN Brussels
Sao Paulo
Bogota
As of 4:08 PM 04/16/14 All times are local (Market data is delayed by at least 15 minutes).
text size: T | T
Back to Snapshot
Company Description

Contact Info

235 East 42nd Street

New York, NY 10017

United States

Phone: 212-733-2323

Fax:

Pfizer Inc. operates as a research-based, global biopharmaceutical company. The company’s portfolio includes medicines and vaccines, as well as consumer healthcare products. The company collaborates with healthcare providers, governments and local communities to support and expand access to affordable healthcare around the world. Segments The company manages its operations through four segments: Primary Care; Specialty Care and Oncology; Established Products and Emerging Markets; and Consumer Healthcare. Primary Care This segment includes prescription pharmaceutical products primarily prescribed by primary-care physicians, and included products in the following therapeutic and disease areas: Alzheimer’s disease, cardiovascular (excluding pulmonary arterial hypertension), erectile dysfunction, genitourinary, major depressive disorder, pain, respiratory and smoking cessation. Products in this segment in 2013 included Celebrex, Chantix/Champix, Eliquis, Lyrica, Premarin, Pristiq and Viagra (outside Canada and South Korea). Specialty Care and Oncology This segment comprises the Specialty Care business unit and the Oncology business unit. Specialty Care business unit includes prescription pharmaceutical products primarily prescribed by physicians who are specialists, and included products in the following therapeutic and disease areas: anti-infectives, endocrine disorders, hemophilia, inflammation, ophthalmology, pulmonary arterial hypertension, specialty neuroscience and vaccines. Its products in this business unit in 2013 included BeneFIX, Enbrel, Genotropin, Geodon (outside the U.S.), the Prevnar family of products, ReFacto AF, Revatio (outside the U.S.), Tygacil, Vfend (outside the U.S. and South Korea), Vyndaqel, Xalatan (outside the U.S., Canada, South Korea, developed Europe, Australia and New Zealand), Xeljanz, Xyntha and Zyvox. Oncology business unit includes prescription pharmaceutical products addressing oncology and oncology-related illnesses. The products in this business unit in 2013 included Inlyta, Sutent, Torisel, Xalkori, Mylotarg (in Japan), Bosulif (in the U.S. and European Union (EU)) and Aromasin (in Japan and South Korea). Established Products and Emerging Markets This segment comprises the Established Products business unit and the Emerging Markets business unit. Established Products business unit includes prescription pharmaceutical products that had lost patent protection or marketing exclusivity in certain countries and/or regions. Products in this business unit in 2013 included Arthrotec, Effexor, Geodon (in the U.S.), Lipitor, Medrol, Norvasc, Protonix, Relpax, Vfend (in the U.S. and South Korea), Xalatan (in the U.S., Canada, South Korea, developed Europe, Australia and New Zealand), Zosyn/Tazocin and Viagra (in Canada and South Korea). Emerging Markets business unit includes all prescription pharmaceutical products sold in emerging markets, including Asia (excluding Japan and South Korea), Latin America, the Middle East, Eastern Europe, Africa, Turkey and Central Europe. Consumer Healthcare This segment includes worldwide revenues from non-prescription products in the following therapeutic categories: dietary supplements, pain management, respiratory and personal care. In 2013, products marketed by Consumer Healthcare included Advil, Caltrate, Centrum, ChapStick, Emergen-C, Preparation H and Robitussin. Biopharmaceutical Products In 2013, the biopharmaceutical business was composed of the following five business units: Primary Care, Specialty Care, Oncology, Established Products and Emerging Markets. The company has entered into collaboration and/or co-promotion agreements relating to certain biopharmaceutical products, including Aricept, Enbrel (in the U.S. and Canada), Spiriva and Rebif. Other Products Consumer Healthcare: The Consumer Healthcare business operates in various geographic markets: the U.S., China, Canada, Germany, Italy, Brazil, Colombia, Russia, Australia and France. Major categories and product lines in its Consumer Healthcare business include the following: Dietary Supplements: Centrum brands (including Centrum, Centrum Silver, Centrum Men’s and Women’s, Centrum Specialist, Centrum Flavor Burst, and Centrum Kids), Caltrate, and Emergen-C; Pain Management: Advil brands (including Advil, Advil PM, Advil Liqui-Gels, Advil Film Coated, Children’s Advil, Infants’ Advil and Advil Migraine), and ThermaCare; Respiratory: Robitussin, Advil Cold & Sinus, Advil Congestion Relief, and Dimetapp; and Personal Care: ChapStick and Preparation H. Animal Health In 2013, the company completed the full disposition of its Animal Health business, which was a business that discovered, developed, manufactured and commercialized animal health medicines and vaccines. Research and Development The company spent $6.7 billion in 2013 on research and development expenses. Customers During 2013, the company’s major customers included McKesson, Inc.; Cardinal Health, Inc.; and AmerisourceBergen Corporation. Regulations The company’s activities are subject to the jurisdiction of other federal regulatory and enforcement departments and agencies, such as the Department of Health and Human Services (HHS) Office of the Inspector General (OIG), the Federal Trade Commission (FTC) (which also has the authority to regulate the advertising of consumer healthcare products, including OTC drugs and dietary supplements), the Department of Justice (DOJ) and the SEC. History Pfizer Inc. was founded in 1849. The company was incorporated under the laws of the state of Delaware in 1942.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
PFE*:MM $391.75 MXN +0.08

PFE* Competitors

Market data is delayed at least 15 minutes.

Company Last Change
GlaxoSmithKline PLC 1,559 GBp -4.50
Merck & Co Inc $56.47 USD +0.21
Novartis AG SFr.74.70 CHF +0.35
Roche Holding AG SFr.254.90 CHF +0.70
Sanofi €75.48 EUR +0.71
View Industry Companies
 

Industry Analysis

PFE*

Industry Average

Valuation PFE* Industry Range
Price/Earnings 18.4x
Price/Sales 3.8x
Price/Book 2.5x
Price/Cash Flow 7.3x
TEV/Sales 2.4x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact PFIZER INC, please visit www.pfizer.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.